Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 15/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | PPARA | Q07869 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | CLK2 | P49760 | 3/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.46 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4249825 | 0.92 | HDAC1 (0.48) | CLK1HDAC1NPC1 | |
| SCHEMBL445756 | 0.91 | CLK1 (0.61) | CLK1HDAC1PPARANPC1CLK2 | |
| SCHEMBL4255195 | 0.90 | NPC1 (0.51) | CLK1HDAC1NPC1 | |
| SCHEMBL4257504 | 0.89 | HDAC1 (0.47) | CLK1HDAC1NPC1 | |
| SCHEMBL4253298 | 0.88 | HDAC1 (0.45) | CLK1HDAC1NPC1CLK2DYRK1A | |
| SCHEMBL4252178 | 0.87 | NPC1 (0.47) | CLK1HDAC1NPC1 | |
| SCHEMBL4252262 | 0.87 | HDAC1 (0.52) | CLK1HDAC1NPC1 | |
| SCHEMBL4251113 | 0.84 | RAB9A (0.57) | CLK1HDAC1 | |
| SCHEMBL443592 | 0.82 | HDAC1 (0.54) | CLK1HDAC1NPC1 | |
| SCHEMBL445237 | 0.81 | NPC1 (0.57) | CLK1HDAC1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023798-A1 | THIOHYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS, INC. (US) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023798-A1 | THIOHYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC8, HDAC3 | CLK1 3179/4885HDAC1 1/4885PPARA 742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.